Trial Outcomes & Findings for Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (NCT NCT01306045)
NCT ID: NCT01306045
Last Updated: 2024-10-01
Results Overview
To determine the feasibility of the use of tumor molecular profiling and targeted therapies in the treatment of Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies, the trial will be evaluated by determining the percentage of enrolled participants with a genomic abnormality. Identifying molecular profiles may help identify new targeted treatments for cancer.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
647 participants
Primary outcome timeframe
1 year and 11 months
Results posted on
2024-10-01
Participant Flow
CUSTOM (Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies). For efficacy, analysis data has been separated by type of intervention for each type of malignancy, e.g., Non-Small Cell Lung Cancer (NSCLC) pts receiving erlotinib, selumetinib etc. since results depend on the type of drug being administered.
Participant milestones
| Measure |
Participants With Non-Small Cell Lung Cancer
Participants with tumors harboring epidermal growth factor receptor (EGFR) mutations; received Erlotinib 150 mg by mouth (PO) every morning (QAM); Participants with tumors harboring Kirsten rat sarcoma virus (KRAS), Harvey Rat sarcoma virus (HRAS), Neuroblastoma-RAS (NRAS), or proto-oncogene B-Raf (BRAF) mutations; received Selumetinib Sulfate (AZD6244) 75 mg by mouth (PO) every (Q) 12 Hours; Participants with tumors harboring phosphatase and tensin homolog (PTEN), protein kinase B (AKT) 1, or catalytic subunit alpha (PIK3CA) mutations; received MK-2206 200 mg by mouth (PO) every day (QD); Participants with tumors harboring -erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) mutations or amplifications; received Lapatinib 1500 mg by mouth (PO) every day (QD); Participants with tumors harboring KIT or platelet-derived growth factor receptor A, (PDGFRA) mutations or amplifications; received Sunitinib 50 mg by mouth (PO) every day (QD).
|
Participants With Small Cell Lung Cancer
Participants with tumors harboring epidermal growth factor receptor (EGFR) mutations; received Erlotinib 150 mg by mouth (PO) every morning (QAM); Participants with tumors harboring Kirsten rat sarcoma virus (KRAS),, Harvey Rat sarcoma virus (HRAS), Neuroblastoma-RAS (NRAS), or proto-oncogene B-Raf (BRAF) mutations; received Selumetinib Sulfate (AZD6244) 75 mg by mouth (PO) every (Q) 12 Hours; Participants with tumors harboring phosphatase and tensin homolog (PTEN), protein kinase B (AKT) 1, or catalytic subunit alpha (PIK3CA) mutations; received MK-2206 200 mg by mouth (PO) every day (QD); Participants with tumors harboring -erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) mutations or amplifications; received Lapatinib 1500 mg by mouth (PO) every day (QD); Participants with tumors harboring KIT or P platelet-derived growth factor receptor A, (PDGFRA) mutations or amplifications; received Sunitinib 50 mg by mouth (PO) every day (QD).
|
Participants With Thymic Malignancies
Participants with tumors harboring epidermal growth factor receptor (EGFR) mutations; received Erlotinib 150 mg by mouth (PO) every morning (QAM); Participants with tumors harboring Kirsten rat sarcoma virus (KRAS),, Harvey Rat sarcoma virus (HRAS), Neuroblastoma-RAS (NRAS), or proto-oncogene B-Raf (BRAF) mutations; received Selumetinib Sulfate (AZD6244) 75 mg by mouth (PO) every (Q) 12 Hours; Participants with tumors harboring phosphatase and tensin homolog (PTEN), protein kinase B (AKT) 1, or catalytic subunit alpha (PIK3CA) mutations; received MK-2206 200 mg by mouth (PO) every day (QD); Participants with tumors harboring -erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) mutations or amplifications; received Lapatinib 1500 mg by mouth (PO) every day (QD); Participants with tumors harboring KIT or platelet-derived growth factor receptor A, (PDGFRA) mutations or amplifications; received Sunitinib 50 mg by mouth (PO) every day (QD).
|
|---|---|---|---|
|
Met General Eligibility Criteria
STARTED
|
481
|
68
|
98
|
|
Met General Eligibility Criteria
Had EGFR Mutations
|
88
|
1
|
1
|
|
Met General Eligibility Criteria
Had KRAS, HRAS, NRAS, or BRAF Mutations
|
103
|
5
|
2
|
|
Met General Eligibility Criteria
Had PTEN, Akt1, or PIK3CA Abnormalities
|
22
|
7
|
2
|
|
Met General Eligibility Criteria
Had ERBB2 Mutations or Amplifications
|
13
|
1
|
1
|
|
Met General Eligibility Criteria
Had KIT or PDGFRA Mutations or Amplifications
|
5
|
1
|
5
|
|
Met General Eligibility Criteria
Enrolled Onto Treatment Arm
|
38
|
4
|
3
|
|
Met General Eligibility Criteria
COMPLETED
|
288
|
57
|
90
|
|
Met General Eligibility Criteria
NOT COMPLETED
|
193
|
11
|
8
|
|
Treatments Received
STARTED
|
38
|
4
|
3
|
|
Treatments Received
Received Erlotinib: Arm 1, Arm 2, and Arm 3 Respectively.
|
15
|
0
|
1
|
|
Treatments Received
Received Selumetinib: Arm 4, Arm 5, and Arm 6 Respectively.
|
9
|
1
|
0
|
|
Treatments Received
Received MK2206: Arm 7, Arm 8, and Arm 9 Respectively.
|
4
|
2
|
1
|
|
Treatments Received
Received Lapatinib: Arm 10, Arm 11, and Arm 12 Respectively.
|
6
|
1
|
0
|
|
Treatments Received
Received Sunitinib: Arm 13, Arm 14, and Arm 15 Respectively.
|
2
|
0
|
1
|
|
Treatments Received
COMPLETED
|
36
|
4
|
3
|
|
Treatments Received
NOT COMPLETED
|
2
|
0
|
0
|
Reasons for withdrawal
| Measure |
Participants With Non-Small Cell Lung Cancer
Participants with tumors harboring epidermal growth factor receptor (EGFR) mutations; received Erlotinib 150 mg by mouth (PO) every morning (QAM); Participants with tumors harboring Kirsten rat sarcoma virus (KRAS), Harvey Rat sarcoma virus (HRAS), Neuroblastoma-RAS (NRAS), or proto-oncogene B-Raf (BRAF) mutations; received Selumetinib Sulfate (AZD6244) 75 mg by mouth (PO) every (Q) 12 Hours; Participants with tumors harboring phosphatase and tensin homolog (PTEN), protein kinase B (AKT) 1, or catalytic subunit alpha (PIK3CA) mutations; received MK-2206 200 mg by mouth (PO) every day (QD); Participants with tumors harboring -erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) mutations or amplifications; received Lapatinib 1500 mg by mouth (PO) every day (QD); Participants with tumors harboring KIT or platelet-derived growth factor receptor A, (PDGFRA) mutations or amplifications; received Sunitinib 50 mg by mouth (PO) every day (QD).
|
Participants With Small Cell Lung Cancer
Participants with tumors harboring epidermal growth factor receptor (EGFR) mutations; received Erlotinib 150 mg by mouth (PO) every morning (QAM); Participants with tumors harboring Kirsten rat sarcoma virus (KRAS),, Harvey Rat sarcoma virus (HRAS), Neuroblastoma-RAS (NRAS), or proto-oncogene B-Raf (BRAF) mutations; received Selumetinib Sulfate (AZD6244) 75 mg by mouth (PO) every (Q) 12 Hours; Participants with tumors harboring phosphatase and tensin homolog (PTEN), protein kinase B (AKT) 1, or catalytic subunit alpha (PIK3CA) mutations; received MK-2206 200 mg by mouth (PO) every day (QD); Participants with tumors harboring -erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) mutations or amplifications; received Lapatinib 1500 mg by mouth (PO) every day (QD); Participants with tumors harboring KIT or P platelet-derived growth factor receptor A, (PDGFRA) mutations or amplifications; received Sunitinib 50 mg by mouth (PO) every day (QD).
|
Participants With Thymic Malignancies
Participants with tumors harboring epidermal growth factor receptor (EGFR) mutations; received Erlotinib 150 mg by mouth (PO) every morning (QAM); Participants with tumors harboring Kirsten rat sarcoma virus (KRAS),, Harvey Rat sarcoma virus (HRAS), Neuroblastoma-RAS (NRAS), or proto-oncogene B-Raf (BRAF) mutations; received Selumetinib Sulfate (AZD6244) 75 mg by mouth (PO) every (Q) 12 Hours; Participants with tumors harboring phosphatase and tensin homolog (PTEN), protein kinase B (AKT) 1, or catalytic subunit alpha (PIK3CA) mutations; received MK-2206 200 mg by mouth (PO) every day (QD); Participants with tumors harboring -erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) mutations or amplifications; received Lapatinib 1500 mg by mouth (PO) every day (QD); Participants with tumors harboring KIT or platelet-derived growth factor receptor A, (PDGFRA) mutations or amplifications; received Sunitinib 50 mg by mouth (PO) every day (QD).
|
|---|---|---|---|
|
Met General Eligibility Criteria
Screen failures
|
193
|
11
|
8
|
Baseline Characteristics
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Baseline characteristics by cohort
| Measure |
Non-Small Cell Lung Cancer (NSCLC)
n=481 Participants
NSCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Small Cell Lung Cancer (SCLC)
n=68 Participants
SCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Thymic Malignancies
n=98 Participants
Thymic malignancies participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Total
n=647 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
62.59 years
STANDARD_DEVIATION 11.41 • n=99 Participants
|
60.75 years
STANDARD_DEVIATION 9.75 • n=107 Participants
|
53.79 years
STANDARD_DEVIATION 14.22 • n=206 Participants
|
61.06 years
STANDARD_DEVIATION 12.11 • n=7 Participants
|
|
Age, Customized
Age 18-39
|
13 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
30 Participants
n=7 Participants
|
|
Age, Customized
Age 40-64
|
253 Participants
n=99 Participants
|
43 Participants
n=107 Participants
|
55 Participants
n=206 Participants
|
351 Participants
n=7 Participants
|
|
Age, Customized
Age >65
|
215 Participants
n=99 Participants
|
25 Participants
n=107 Participants
|
26 Participants
n=206 Participants
|
266 Participants
n=7 Participants
|
|
Sex: Female, Male
Female
|
249 Participants
n=99 Participants
|
33 Participants
n=107 Participants
|
48 Participants
n=206 Participants
|
330 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
232 Participants
n=99 Participants
|
35 Participants
n=107 Participants
|
50 Participants
n=206 Participants
|
317 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
White
|
384 Participants
n=99 Participants
|
60 Participants
n=107 Participants
|
76 Participants
n=206 Participants
|
520 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
39 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
50 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Asian
|
42 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
56 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Other
|
8 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
9 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Non-Hispanic
|
472 Participants
n=99 Participants
|
67 Participants
n=107 Participants
|
97 Participants
n=206 Participants
|
636 Participants
n=7 Participants
|
|
Region of Enrollment
United States
|
481 participants
n=99 Participants
|
68 participants
n=107 Participants
|
98 participants
n=206 Participants
|
647 participants
n=7 Participants
|
|
Eastern Cooperative Oncology (ECOG) Performance Status
0
|
75 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
13 Participants
n=206 Participants
|
95 Participants
n=7 Participants
|
|
Eastern Cooperative Oncology (ECOG) Performance Status
1
|
322 Participants
n=99 Participants
|
43 Participants
n=107 Participants
|
77 Participants
n=206 Participants
|
442 Participants
n=7 Participants
|
|
Eastern Cooperative Oncology (ECOG) Performance Status
2
|
64 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
83 Participants
n=7 Participants
|
|
Eastern Cooperative Oncology (ECOG) Performance Status
3-4
|
20 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
27 Participants
n=7 Participants
|
|
Histologic Feature of Tumor
Adenocarcinoma
|
363 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
363 Participants
n=7 Participants
|
|
Histologic Feature of Tumor
Squamous cell carcinoma
|
64 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
64 Participants
n=7 Participants
|
|
Histologic Feature of Tumor
Small cell*
|
0 Participants
n=99 Participants
|
65 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
65 Participants
n=7 Participants
|
|
Histologic Feature of Tumor
Thymoma
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
41 Participants
n=206 Participants
|
41 Participants
n=7 Participants
|
|
Histologic Feature of Tumor
Thymic carcinoma
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
48 Participants
n=206 Participants
|
48 Participants
n=7 Participants
|
|
Histologic Feature of Tumor
Other
|
54 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
66 Participants
n=7 Participants
|
|
Smoking History
Never-smokers
|
148 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
NA Participants
n=206 Participants
|
NA Participants
n=7 Participants
|
|
Smoking History
Current or former smokers
|
333 Participants
n=99 Participants
|
63 Participants
n=107 Participants
|
NA Participants
n=206 Participants
|
NA Participants
n=7 Participants
|
PRIMARY outcome
Timeframe: 1 year and 11 monthsPopulation: For tolerability, data has been separated by type of malignancy since the information being conveyed represents overall tolerability in participants with a given malignancy.
To determine the feasibility of the use of tumor molecular profiling and targeted therapies in the treatment of Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies, the trial will be evaluated by determining the percentage of enrolled participants with a genomic abnormality. Identifying molecular profiles may help identify new targeted treatments for cancer.
Outcome measures
| Measure |
Non-Small Cell Lung Cancer (NSCLC)
n=481 Participants
NSCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Small Cell Lung Cancer (SCLC)
n=68 Participants
SCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Thymic Malignancies
n=98 Participants
Thymic malignancies participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
|---|---|---|---|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Tumor protein p53 (TP53)
|
28.5 percentage of participants
|
44.2 percentage of participants
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Kirsten rat sarcoma virus (KRAS)
|
24.9 percentage of participants
|
4.1 percentage of participants
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Epidermal growth factor receptor (EGFR)
|
22.1 percentage of participants
|
2.0 percentage of participants
|
1 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
PDGFRA amplifications
|
12.8 percentage of participants
|
—
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
phosphoinositide 3-kinase (PIK3)CA amplifications
|
11.1 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Anaplastic lymphoma kinase (ALK) trans
|
8.7 percentage of participants
|
—
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Retinoblastoma 1 (RB1)
|
4.8 percentage of participants
|
33.3 percentage of participants
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
SWI/SNF Related, Matrix Associated Actin Dependent Regulator Of ChromatinSubfamilyA Member4(SMARCA4)
|
4.8 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Phosphatase and tensin homolog (PTEN)
|
4.4 percentage of participants
|
9.5 percentage of participants
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
hosphatidylinositol 3-kinase (PIK3CA)
|
3.9 percentage of participants
|
8.5 percentage of participants
|
2 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Neurofibromatosis type 1 (NF1)
|
3.0 percentage of participants
|
6.7 percentage of participants
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
esenchymal-epithelial transition factor (MET)
|
3.0 percentage of participants
|
2.6 percentage of participants
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Human epidermal growth factor receptor 2 (HER2) amplifications
|
2.8 percentage of participants
|
5.6 percentage of participants
|
1 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)
|
0.7 percentage of participants
|
2.2 percentage of participants
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Harvey Rat sarcoma virus (HRAS)
|
0.7 percentage of participants
|
2.3 percentage of participants
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Tet Methylcytosine Dioxygenase 2 (TET2)
|
0.4 percentage of participants
|
6.7 percentage of participants
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
AKT Serine/Threonine Kinase 1 (AKT1)
|
0.4 percentage of participants
|
2.2 percentage of participants
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Discoidin Domain Receptor 2 (DDR2)
|
6.7 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Phosphatidylinositol 3-kinase (PIK3R2)
|
6.7 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Protein Tyrosine Phosphatase Receptor Type D (PTPRD)
|
6.7 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Serine/threonine kinase 11 (STK11)
|
5.5 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A)
|
4.4 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Catenin Beta 1 (CTNNB1)
|
3.4 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2)
|
2.8 percentage of participants
|
—
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Ataxia telangiectasia mutated (ATM)
|
2.4 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Erb-B2 Receptor Tyrosine Kinase 4 (ERBB4)
|
2.4 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF)
|
2.3 percentage of participants
|
2.0 percentage of participants
|
0 percentage of participants
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Smoothened (SMO)
|
1.9 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Neurotrophic Receptor Tyrosine Kinase 3 (NTRK3)
|
1.7 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Phosphoinositide-3-Kinase Regulatory Subunit 1 (PIK3R1)
|
0.8 percentage of participants
|
—
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
Neurogenic locus notch homolog protein 1 (NOTCH1)
|
—
|
4.8 percentage of participants
|
—
|
|
Percentage of Enrolled Participants Testing Positive for Genomic Abnormality
KIT Proto-Oncogene, Receptor Tyrosine Kinase (KIT)
|
—
|
2.6 percentage of participants
|
0 percentage of participants
|
PRIMARY outcome
Timeframe: 1 year and 13 monthsPopulation: Overall number of participants analyzed represent the total number of participants for each tumor type evaluable for response (efficacy) across different treatment arms. For tolerability, data has been separated by type of malignancy since the information being conveyed represents overall tolerability in participants with a given malignancy.
Efficacy will be determined by assessing if participants who have treatment assigned on the basis of their molecular profiling results will exhibit reasonable response to the drug selected for their particular profile. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study Progressive Disease (PD) is At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.
Outcome measures
| Measure |
Non-Small Cell Lung Cancer (NSCLC)
n=36 Participants
NSCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Small Cell Lung Cancer (SCLC)
n=4 Participants
SCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Thymic Malignancies
n=3 Participants
Thymic malignancies participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
|---|---|---|---|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Partial Response with Erlotinib
|
9 Participants
|
—
|
0 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Stable Disease with Erlotinib
|
5 Participants
|
—
|
0 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Partial Response to Lapatinib
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Partial Response with Sunitinib
|
0 Participants
|
—
|
0 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Stable Disease with Sunitinib
|
1 Participants
|
—
|
1 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Progressive Disease with Sunitinib
|
1 Participants
|
—
|
0 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Stable Disease with Selumetinib
|
4 Participants
|
0 Participants
|
—
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Progressive Disease with Erlotinib
|
1 Participants
|
—
|
1 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Stable Disease with Lapatinib
|
4 Participants
|
1 Participants
|
—
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Progressive Disease with Lapatinib
|
2 Participants
|
0 Participants
|
—
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Partial Response with Selumetinib
|
1 Participants
|
0 Participants
|
—
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Progressive Disease with Selumetinib
|
4 Participants
|
1 Participants
|
—
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Partial Response with MK2206
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Stable Disease with MK2206
|
4 Participants
|
0 Participants
|
1 Participants
|
|
Number of Evaluable Participants With a Response Based on Molecular Profile Directed Treatments in Non-Small Cell Lung Cancer, (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Malignancies
Progressive Disease with MK2206
|
0 Participants
|
2 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: 1 year and 13 monthsPopulation: Overall number of participants analyzed represent the total number of participants for each tumor type evaluable for response (efficacy) across different treatment arms. For tolerability, data has been separated by type of malignancy since the information being conveyed represents overall tolerability in participants with a given malignancy.
Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).Partial Response (PD) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study Progressive Disease (PD) is At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.
Outcome measures
| Measure |
Non-Small Cell Lung Cancer (NSCLC)
n=36 Participants
NSCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Small Cell Lung Cancer (SCLC)
n=4 Participants
SCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Thymic Malignancies
n=3 Participants
Thymic malignancies participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
|---|---|---|---|
|
Percentage of Evaluable Participants Overall Response Rate (ORR) Based on the Drug Selected for Their Particular Profile
Overall response rate to Lapatinib
|
0 percentage of participants
Interval 0.0 to 0.0
|
0 percentage of participants
Interval 0.0 to 0.0
|
—
|
|
Percentage of Evaluable Participants Overall Response Rate (ORR) Based on the Drug Selected for Their Particular Profile
Overall response rate to Sunitinib
|
0 percentage of participants
Interval 0.0 to 0.0
|
—
|
0 percentage of participants
Interval 0.0 to 0.0
|
|
Percentage of Evaluable Participants Overall Response Rate (ORR) Based on the Drug Selected for Their Particular Profile
Overall response rate to MK2206
|
0 percentage of participants
Interval 0.0 to 0.0
|
0 percentage of participants
Interval 0.0 to 0.0
|
0 percentage of participants
Interval 0.0 to 0.0
|
|
Percentage of Evaluable Participants Overall Response Rate (ORR) Based on the Drug Selected for Their Particular Profile
Overall response rate to Erlotinib
|
60 percentage of participants
Interval 32.3 to 83.7
|
—
|
0 percentage of participants
Interval 0.0 to 0.0
|
|
Percentage of Evaluable Participants Overall Response Rate (ORR) Based on the Drug Selected for Their Particular Profile
Overall response rate to Selumetinib
|
11 percentage of participants
Interval 0.0 to 48.0
|
0 percentage of participants
Interval 0.0 to 0.0
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 5 yearsPopulation: As pre-specified in the protocol, only the NSCLC group is reported here.
The frequency of EGFR germline mutations will be determined by enrolling participants from families with high susceptibility to lung cancer and their first-degree relatives (at the National Cancer Institute (NCI) site only). Individuals were tested for Epidermal Growth Factor Receptor (EGFR) Germline Mutations if they consented to participation in the study and had a personal history of invasive NSCLC or one of the pre-invasive histologies associated with the development of non-small cell lung cancer (NSCLC) and more than two affected family members with invasive NSCLC or one of the pre-invasive histologies associated with the development of NSCLC; OR a first-degree relative with a known EGFR germline mutation (EGFR threonine (T) with methionine (M) at position 790 of exon 20 (T790M), exon 21 V843I, exon 21 R831C and exon 20 R776G).
Outcome measures
| Measure |
Non-Small Cell Lung Cancer (NSCLC)
n=19 Participants
NSCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Small Cell Lung Cancer (SCLC)
SCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Thymic Malignancies
Thymic malignancies participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
|---|---|---|---|
|
Frequency of Epidermal Growth Factor Receptor (EGFR) Germline Mutations in Families With High Susceptibility to Lung Cancer
|
36.8 percentage of participants
|
—
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.Population: Serious and/or Non-Serious adverse events data was collected for 423/647 participants because the remainder did not undergo any study-related intervention because a new biopsy was not performed (archival tissue was used for molecular profiling) and/or the participant failed to enroll in one of the treatment arms. For tolerability, data has been separated by type of malignancy since the information being conveyed represents overall tolerability in participants with a given malignancy.
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Outcome measures
| Measure |
Non-Small Cell Lung Cancer (NSCLC)
n=310 Participants
NSCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Small Cell Lung Cancer (SCLC)
n=22 Participants
SCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
Thymic Malignancies
n=91 Participants
Thymic malignancies participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
|
|---|---|---|---|
|
Here is the Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)
|
37 Participants
|
1 Participants
|
3 Participants
|
Adverse Events
Non-Small Cell Lung Cancer (NSCLC)
Serious events: 15 serious events
Other events: 37 other events
Deaths: 467 deaths
Small Cell Lung Cancer (SCLC)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 68 deaths
Thymic Malignancies
Serious events: 3 serious events
Other events: 3 other events
Deaths: 88 deaths
Serious adverse events
| Measure |
Non-Small Cell Lung Cancer (NSCLC)
n=310 participants at risk
NSCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
This protocol was designed to evaluate the feasibility of using tumor molecular profile and targeted therapies in the treatment of advanced thoracic malignancies. Assessment of adverse events (AEs) per therapeutic intervention was not an objective of this trial. Therefore, we have reported adverse events in aggregate form per histology and not as AEs per therapeutic intervention per histology.
|
Small Cell Lung Cancer (SCLC)
n=22 participants at risk
SCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
This protocol was designed to evaluate the feasibility of using tumor molecular profile and targeted therapies in the treatment of advanced thoracic malignancies. Assessment of adverse events (AEs) per therapeutic intervention was not an objective of this trial. Therefore, we have reported adverse events in aggregate form per histology and not as AEs per therapeutic intervention per histology.
|
Thymic Malignancies
n=91 participants at risk
Thymic malignancies participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
This protocol was designed to evaluate the feasibility of using tumor molecular profile and targeted therapies in the treatment of advanced thoracic malignancies. Assessment of adverse events (AEs) per therapeutic intervention was not an objective of this trial. Therefore, we have reported adverse events in aggregate form per histology and not as AEs per therapeutic intervention per histology.
|
|---|---|---|---|
|
Blood and lymphatic system disorders
Anemia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Bronchial infection
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Bronchopulmonary hemorrhage
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
General disorders
Death NOS
|
2.3%
7/310 • Number of events 7 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Dehydration
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Esophageal hemorrhage
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Injury, poisoning and procedural complications
Fracture
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Lung infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Nausea
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, Death during follow up
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, Malignant Disease
|
1.3%
4/310 • Number of events 4 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Musculoskeletal and connective tissue disorders
Non-cardiac chest pain
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Upper respiratory infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Renal and urinary disorders
Urinary retention
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Urinary tract infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Vomiting
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Injury, poisoning and procedural complications
Wound complication
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Injury, poisoning and procedural complications
Wound dehiscence
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
Other adverse events
| Measure |
Non-Small Cell Lung Cancer (NSCLC)
n=310 participants at risk
NSCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
This protocol was designed to evaluate the feasibility of using tumor molecular profile and targeted therapies in the treatment of advanced thoracic malignancies. Assessment of adverse events (AEs) per therapeutic intervention was not an objective of this trial. Therefore, we have reported adverse events in aggregate form per histology and not as AEs per therapeutic intervention per histology.
|
Small Cell Lung Cancer (SCLC)
n=22 participants at risk
SCLC participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
This protocol was designed to evaluate the feasibility of using tumor molecular profile and targeted therapies in the treatment of advanced thoracic malignancies. Assessment of adverse events (AEs) per therapeutic intervention was not an objective of this trial. Therefore, we have reported adverse events in aggregate form per histology and not as AEs per therapeutic intervention per histology.
|
Thymic Malignancies
n=91 participants at risk
Thymic malignancies participants received Erlotinib 150 mg by mouth (PO) every morning (QAM), Selumetinib (AZD6244) Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours, MK-2206 200 mg by mouth (PO) every (Q) Week, Lapatinib 1500 mg by mouth (PO) every day (QD), and/or Sunitinib 50 mg by mouth (PO) on days 1-28.
This protocol was designed to evaluate the feasibility of using tumor molecular profile and targeted therapies in the treatment of advanced thoracic malignancies. Assessment of adverse events (AEs) per therapeutic intervention was not an objective of this trial. Therefore, we have reported adverse events in aggregate form per histology and not as AEs per therapeutic intervention per histology.
|
|---|---|---|---|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.65%
2/310 • Number of events 3 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Bloating
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Blood bilirubin increased
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Eye disorders
Blurred vision
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Bronchial infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Bronchopulmonary hemorrhage
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
CPK increased
|
0.97%
3/310 • Number of events 5 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Eye disorders
Conjunctivitis
|
0.97%
3/310 • Number of events 3 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Constipation
|
1.3%
4/310 • Number of events 4 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Creatinine increased
|
0.97%
3/310 • Number of events 3 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Psychiatric disorders
Depression
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Diarrhea
|
2.9%
9/310 • Number of events 10 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Nervous system disorders
Dizziness
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Eye disorders
Dry eye
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Dry mouth
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Reproductive system and breast disorders
Dyspareunia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Dyspepsia
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Dysphagia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.65%
2/310 • Number of events 3 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
4.5%
1/22 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
General disorders
Edema face
|
1.3%
4/310 • Number of events 6 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
General disorders
Edema limbs
|
1.3%
4/310 • Number of events 7 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Erythroderma
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Eye disorders
Eye disorders - Other, Periorbital edema
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Eye disorders
Eye disorders - Other, Elongated Eyelashes
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Eye infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Injury, poisoning and procedural complications
Fall
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
General disorders
Fatigue
|
2.9%
9/310 • Number of events 10 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
4.5%
1/22 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
2.2%
2/91 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
General disorders
Fever
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Eye disorders
Flashing lights
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Flatulence
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
General disorders
Flu like symptoms
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Injury, poisoning and procedural complications
Fracture
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, Mouth ulcers
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, Sensation of swollen tongue
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
4.5%
1/22 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Gastrointestinal pain
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
4.5%
1/22 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Gum infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Nervous system disorders
Headache
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Hoarseness
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Vascular disorders
Hot flashes
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
0.32%
1/310 • Number of events 3 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
0.32%
1/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypernatremia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Vascular disorders
Hypertension
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Hypertrichosis
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypertriglyceridemia
|
0.32%
1/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
2.9%
9/310 • Number of events 16 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
1.3%
4/310 • Number of events 6 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
1.6%
5/310 • Number of events 6 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Vascular disorders
Hypotension
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Endocrine disorders
Hypothyroidism
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Infections and infestations - Other, Viral Infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
General disorders
Infusion site extravasation
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Psychiatric disorders
Insomnia
|
1.3%
4/310 • Number of events 4 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Lipase increased
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Lung infection
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Lymphocyte count decreased
|
4.2%
13/310 • Number of events 22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
3.3%
3/91 • Number of events 7 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Lymphocyte count increased
|
0.32%
1/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Mucosal infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Mucositis oral
|
2.6%
8/310 • Number of events 10 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Nausea
|
3.9%
12/310 • Number of events 13 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Neutrophil count decreased
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 3 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysesthesia syndrome
|
0.97%
3/310 • Number of events 5 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Papulopustular rash
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Nervous system disorders
Paresthesia
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Paronychia
|
1.3%
4/310 • Number of events 6 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Eye disorders
Periorbital edema
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Platelet count decreased
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.65%
2/310 • Number of events 4 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
4.5%
1/22 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Nervous system disorders
Presyncope
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
1.3%
4/310 • Number of events 5 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
2.9%
9/310 • Number of events 11 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
4.5%
1/22 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
2.9%
9/310 • Number of events 14 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Serum amylase increased
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Cardiac disorders
Sinus bradycardia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, Ichthyosis
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Skin infection
|
0.97%
3/310 • Number of events 4 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Nervous system disorders
Syncope
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Vascular disorders
Thromboembolic event
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Upper respiratory infection
|
0.97%
3/310 • Number of events 3 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Urinary tract infection
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Reproductive system and breast disorders
Vaginal dryness
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Voice alteration
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Vomiting
|
1.6%
5/310 • Number of events 6 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Eye disorders
Watering eyes
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Weight loss
|
0.32%
1/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
White blood cell decreased
|
0.97%
3/310 • Number of events 4 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Injury, poisoning and procedural complications
Wound dehiscence
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Infections and infestations
Wound infection
|
0.00%
0/310 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Gastrointestinal disorders
Abdominal pain
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
—
0/0 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Alanine aminotransferase increased
|
2.3%
7/310 • Number of events 8 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
—
0/0 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Alkaline phosphatase increased
|
1.9%
6/310 • Number of events 10 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
—
0/0 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Immune system disorders
Allergic reaction
|
0.65%
2/310 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
—
0/0 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
—
0/0 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.97%
3/310 • Number of events 4 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
—
0/0 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Blood and lymphatic system disorders
Anemia
|
3.2%
10/310 • Number of events 17 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
2.2%
2/91 • Number of events 2 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Metabolism and nutrition disorders
Anorexia
|
1.6%
5/310 • Number of events 8 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Psychiatric disorders
Anxiety
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.32%
1/310 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/91 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
|
Investigations
Aspartate aminotransferase increased
|
2.3%
7/310 • Number of events 7 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
0.00%
0/22 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
1.1%
1/91 • Number of events 1 • Date treatment consent signed to date off study, approximately 122 months and 25 days, 88 months and 16 days, and 126 months and 2 days for each group respectively.
Data was collected for 423/647 participants(pts) because the remainder did not undergo any study-related intervention because a new biopsy wasn't performed(archival tissue was used for molecular profiling)and/or the pt failed to enroll in one of the treatment arms.All pts included in the mortality section. Data reported as an aggregate of events observed in pts with each tumor type who received any type of drug intervention (data is reported per tumor type and not per type of drug intervention).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place